New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
06:39 EDTICPTIntercept trial deaths unlikely associated with treatment, says Wedbush
Wedush believes the two deaths that occurred during the FLINT Phase 2b trial disclosed late Friday by Intercept are unlikely related to the OCA treatment. The firm says any continued weakness in shares of Intercept would be a buying opportunity and keeps an Outperform rating on the name with a $493 price target.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use